Anti-human IgM monoclonal antibody hybridoma cell strain, monoclonal antibody and application thereof
Anti-human IgM monoclonal antibodies were prepared through autonomous naturally purified human IgM-Fc fragments and hybridoma cell technology, which solved the problem of poor quality of existing products and achieved high activity, high specificity and stability of antibody preparation, suitable for use in the process of Massive production and application.
Patent Information
- Application Number
- CN202411481191.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-23
- Publication Date
- 2024-12-06
AI Technical Summary
The quality of existing anti-human IgM monoclonal antibody products is uneven, the preparation process is cumbersome and the cost is high, resulting in low activity, poor specificity, many cross-reactions, poor stability and short validity.
The anti-human IgM monoclonal antibody hybridoma cell line IgM2 was prepared by hybridoma cell technology using autonomous naturally purified human IgM-Fc fragments as immunogens. After screening and purification, high-purity and high-specific antibodies were obtained, and sucrose was concentrated and Sterile filter membrane filtration technology improves the stability and purity of antibodies.
The high activity and specificity of anti-human IgM monoclonal antibodies are achieved, the cross-reaction is reduced, the stability and storage time of the antibodies are improved, and it is suitable for large-scale production and application.
Smart Images

Figure CN119082045A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of immunology and in vitro diagnostic detection technology, and in particular to an anti-human IgM monoclonal antibody hybridoma cell line, a monoclonal antibody and applications thereof. Background Art
[0002] Anti-human IgM monoclonal antibody is a monoclonal antibody against human immunoglobulin M (IgM). IgM is the immunoglobulin with the largest molecular weight. It is mainly distributed in serum and is the first antibody synthesized by the body. It plays a pioneering role in the early stage of infection. Clinically, the detection of IgM antibodies can be used as one of the indicators for early diagnosis of certain infectious diseases. Anti-human IgM monoclonal antibodies are widely used in clinical testing, diagnosis and epidemiological surveys due to their high specificity.
[0003] In recent years, monoclonal antibody technology has been developing continuously. At present, different types of monoclonal antibodies such as hybridoma technology, chimeric monoclonal antibodies, and fully humanized monoclonal antibodies are widely used. Hybridoma technology is to fuse mouse myeloma cells that cannot produce specific antibodies with pure mouse B cells immunized with specific antigens in vitro to form a hybrid cell line, and produce monoclonal antibodies through multiple cloning and screening. Chimeric monoclonal antibodies use genetic engineering technology to replace the variable region genes of mouse monoclonal antibodies with the constant region genes of human antibodies, thereby reducing heterogeneity and immunogenicity. Fully humanized monoclonal antibodies use human genetic information to encode antibodies and are suitable for the field of biological antibody drugs. In the process of preparing humanized monoclonal antibodies, multiple steps are involved, including phage antibody library screening, gene cloning, cell culture, protein expression, and purification. Although the proportion of heterologous proteins is reduced, there are disadvantages such as decreased ability to bind to antigens, and even changes in antibody structure and loss of activity. The natural antibodies prepared by traditional hybridoma technology have obvious advantages in purity, activity, structural characterization, and stability, and are more suitable for use in in vitro diagnostic reagents.
[0004] Anti-human IgM monoclonal antibodies, the quality of current market products is uneven. Although anti-IgMμ chain monoclonal antibodies can be widely used as labeled secondary antibodies in the early diagnosis of infectious diseases and immunological research, the process of preparing anti-IgMμ chain monoclonal antibodies is cumbersome, costly, and cannot be produced and supplied in large quantities in a short period of time. Currently, the products on the market are mainly for human IgM full fragments and IgMμ chains. Most of these monoclonal antibodies have the disadvantages of low activity, poor specificity, many cross-reactions, poor stability, and short shelf life.
[0005] Therefore, the prior art and product performance need to be further improved, and the present invention is hereby proposed. Summary of the invention
[0006] The present invention aims to solve the above problems and provides an anti-human IgM monoclonal antibody hybridoma cell line, a monoclonal antibody and applications thereof.
[0007] Specifically, the technical solution provided by the present application is as follows: In the first aspect, the present application provides an anti-human IgM monoclonal antibody hybridoma cell strain, the hybridoma cell strain is named IgM2, and the deposit number is CCTCC NO.C2024172.
[0008] Furthermore, the preparation method of the hybridoma cell line is:
[0009] Based on the principle of hybridoma cells, we used the naturally purified human IgM-Fc fragment as an immunogen to quickly immunize mice and complete the preparation of hybridomas. The self-developed screening indicators and processes include: positive (human IgM-Fc fragment), specificity (human IgG), subtype (IgG1 subtype), subcloning 3 times, cell passage stability (10 consecutive passages), cell freezing stability (10 times of freezing and thawing). Finally, the anti-human IgM monoclonal antibody hybridoma cell line 2 with stable performance was screened out.
[0010] In a second aspect, the present application provides an anti-human IgM monoclonal antibody, wherein the antibody is secreted and produced by the hybridoma cell line described in the first aspect.
[0011] Furthermore, the preparation method of the monoclonal antibody is:
[0012] Immunize the anti-human IgM monoclonal antibody hybridoma cell line 2, prepare mouse ascites, precipitate with ammonium sulfate, and then purify the antibody through a homemade human IgM-Fc immunoaffinity chromatography column. Then, concentrate the antibody with sucrose, store it in a phosphate buffer containing a final concentration of 5% sucrose, and filter it through a sterile filter membrane with a pore size of 0.22μm to obtain a high-purity and high-specificity anti-human IgM monoclonal antibody.
[0013] In a third aspect, the present invention provides use of the hybridoma cell line described in the first aspect in preparing a kit.
[0014] In a fourth aspect, the present invention provides use of the monoclonal antibody described in the second aspect in preparing a kit.
[0015] Furthermore, the kit is a colloidal gold immunochromatography kit.
[0016] Furthermore, the hybridoma cell line as described in the first aspect is used in the preparation of a Mycoplasma pneumoniae IgM antibody detection reagent.
[0017] Furthermore, the use of the monoclonal antibody as described in the second aspect in the preparation of a Mycoplasma pneumoniae IgM antibody detection reagent.
[0018] Preferably, the final concentration of the anti-human IgM monoclonal antibody is 15-20 μg / ml.
[0019] The present invention has the following advantages / benefits:
[0020] The anti-human IgM monoclonal antibody provided by the present invention can retain the activity of natural antibodies and achieve high specificity and stability of the anti-human IgM monoclonal antibody. The antibody specific to the IgM Fc fragment targets the Fc region of the IgM molecule, while the anti-human IgM antibody may target the antigenic determinant in the Fc region or Fab region of the IgM. The IgM-FC fragment is a part of the IgM μ chain and is a conserved fragment specific to IgM. The antibody produced by immunizing an animal with the IgM-FC fragment as an immunogen can specifically bind to IgM, avoiding the serious cross reaction between the use of whole molecule IgM as an immunogen and other Ig antibodies, and has stronger specificity. The μ chain of IgM contains Fab components, which may bind to some difficult-to-remove foreign proteins, resulting in interference with the specificity of the IgM μ chain. In addition, the preparation process of the IgM-FC fragment is relatively simple and low in cost, which is suitable for large-scale promotion and application. Although IgM-FC fragments can be synthesized in vitro by genetic engineering and efficiently expressed in E. coli, most of them are expressed in inclusion bodies, and protein renaturation is a problem. Moreover, the immunogenicity of the recombinant IgM-FC peptides obtained by recombinant expression is poorer than that of the natural IgM-FC peptides.
[0021] The antibody against the IgM-Fc fragment in the present invention is prepared by immunizing mice with the above-mentioned anti-human IgM monoclonal antibody hybridoma cell line 2 to obtain ascites. Purified by a homemade human IgM-Fc immunoaffinity chromatography column, a single-epitope monoclonal antibody against the IgM-Fc fragment is obtained, which is more specific than the antibody against the IgM fragment and the antibody obtained by the ordinary ProA / ProG ordinary affinity chromatography column or ion chromatography column purification method, and solves the problem of strong cross-reaction of existing antibodies. The present invention adopts a sucrose concentration process to increase the antibody concentration to 5 mg / ml, which is conducive to the long-term storage of antibodies, and antibodies frozen for 3-5 years can still maintain good biological properties. The phosphate buffer system with a final concentration of 5% sucrose can improve the solid phase coating stability of the antigen in the application of diagnostic reagents, thereby ensuring the stability and validity period of the reagent. After filtration through a sterile filter membrane with a pore size of 0.22 μm, impurities such as protein aggregates and bacteria can be effectively removed, thereby improving the purity of the antibody and reducing non-specific reactions.
[0022] The anti-human IgM monoclonal antibody hybridoma cell line 2 provided by the present invention can obtain the following corresponding advantages or beneficial effects through the following self-developed screening process:
[0023]
[0024] BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. Obviously, the drawings described below are only one embodiment of the present invention, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.
[0026] Figure 1 : The hybridoma cell line of the present invention is stable in passage;
[0027] Figure 2 : The cryopreservation and recovery stability of the hybridoma cell line of the present invention;
[0028] Figure 3 : Purity identification result of anti-human IgM monoclonal antibody 2 of the present invention;
[0029] Figure 4 : Comparative results of colloidal gold immunochromatography test of strong positive clinical samples in Example 5 of the present invention;
[0030] Figure 5 : Comparison results of colloidal gold immunochromatography test of moderate-positive clinical samples and weak-positive clinical samples in Example 5 of the present invention;
[0031] Figure 6 : Comparative results of negative clinical sample colloidal gold immunochromatography test in Example 5 of the present invention;
[0032] Figure 7 : A comparison chart of background detection in negative clinical samples in Example 5 of the present invention;
[0033] Figure 8 : Comparison of weak positive clinical samples using different antibody purification methods in Example 5 of the present invention;
[0034] Fig. 9 : Comparison of positive clinical samples of different antibody purification methods in Example 5 of the present invention;
[0035] Fig.10 : Comparison of negative clinical samples of different antibody purification methods in Example 5 of the present invention. DETAILED DESCRIPTION
[0036] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. The following embodiments are only for illustrating the present invention, and are not intended to limit the scope of the present invention in any way. Based on the embodiments in the present invention, all other embodiments obtained by those skilled in the art without making creative work are within the scope of protection of the present invention. The experimental methods used in the present invention are conventional methods unless otherwise specified. The materials, reagents, etc. used in the present invention, unless otherwise specified, can be obtained from commercial channels. In addition, other terms used in the present invention, unless otherwise specified, generally have the meanings commonly understood by those of ordinary skill in the art.
[0037] Example 1: Cell line preservation
[0038] The hybridoma cell line IgM2 of the present invention is deposited in the China Center for Type Culture Collection, located at China-Wuhan-Wuhan University Collection Center, with a deposit number of CCTCC NO.C2024172.
[0039] Example 2: Preparation of hybridoma cell lines secreting anti-human IgM monoclonal antibodies.
[0040] 1. Immunogen Preparation
[0041] 1.1 Preparation of immunogen: human IgM-Fc fragment The preparation method of human IgM Fc fragment includes two steps: purifying IgM from normal human serum and separating Fc fragment using enzymatic hydrolysis technology.
[0042] 1.1.1 Preparation of human IgM. Normal human serum is pre-treated by centrifugation and filtration to remove lipoproteins. Human IgM is then initially concentrated and separated from the pre-treated human serum by polyethylene glycol precipitation. Protein removal is then performed: affinity chromatography (protein G) is used to remove human IgG, and then ion exchange chromatography (hydroxyapatite is used to remove impurities) is performed to further purify human IgM.
[0043] 1.1.2 Preparation of human IgM-Fc fragments. Enzymatic digestion: Use trypsin to digest at 56°C for 1 hour to obtain IgM-Fc fragments. The enzymatically digested IgM-Fc fragments are purified by ion exchange chromatography and gel filtration chromatography to obtain high-purity and high-stability IgM-Fc fragments.
[0044] 2. Mouse Immunization
[0045] Immunization: Select 6-week-old female BALB / c mice. For the first immunization, the antigen and mouse rapid adjuvant (3W) were mixed and emulsified in equal volumes, and the mice were immunized through the calf muscle of the hind legs, with an immunization dose of 20μg / mouse. After the 14th day, a booster immunization was performed in the same way, with an immunization dose of 15μg / mouse. On the 21st day, a trace amount of tail blood was collected to measure the titer. Fusion can be performed when the serum titer reaches more than 100,000. Three days before fusion, the mice were immunized with intraperitoneal shock, 20μg / mouse.
[0046] 3. Cell Fusion
[0047] Under sterile conditions, the spleen of the immunized mouse was taken, fully ground and dispersed, centrifuged at 1000rpm for 10min, mouse lymphocytes were collected, mixed with mouse myeloma cells sp2 / 0 at a ratio of 5:1, and the cells were washed by centrifugation; in a 37°C water bath, 1ml PEG (molecular weight 1450) was added dropwise within 1min for cell fusion. Fusion was terminated with serum-free DMEM. After 15min, centrifuged at 800rpm for 10min, resuspended with HAT medium, and dispensed into 96-well cell culture plates, and cultured at 37°C in an incubator containing 5% carbon dioxide.
[0048] 4. Hybridoma cell screening and subcloning
[0049] On the fifth day, the fusion cells were half-changed with HAT medium, and on the eighth day, half-changed with medium. On the ninth day, the cell culture supernatant was detected by indirect ELISA. The specific detection method is as follows:
[0050] 4.4.1 Positive screening.
[0051] Dilute human IgM-Fc to 1μg / ml with coating buffer, and coat 100μl / well on the ELISA plate, and coat overnight at 4℃. Wash the plate 3 times. Add 150μl of blocking solution to each well of the ELISA plate, and incubate at 37℃ for 2h. Wash the plate 3 times. Add the supernatant of the cells to be tested to the ELISA plate, 100μl / well, and use mouse immune serum as a positive control, and incubate at 37℃ for 1h. Wash the plate 3 times. Dilute HRP-labeled goat anti-mouse antibody 1:40,000, add it to the ELISA plate, 100μl / well, and incubate at 37℃ for 1h. Wash the plate 5 times. Add 100μl of TMB colorimetric solution to each well of the ELISA plate, incubate at 37℃ for 10min; stop with 2M sulfuric acid, 50μl / well, and read the data at a wavelength of 450nm.
[0052] Table 1 Cell positive screening test results
[0053] Cell number IgM1 IgM2 IgM3 IgM4 IgM5 IgM6 OD value 2.015 2.109 2.031 1.863 1.976 2.006 Cell number IgM7 IgM8 IgM9 IgM10 Negative Positive OD value 2.031 1.985 1.862 1.946 0.113 1.990
[0054] After positive screening, the above 10 cell strains with higher positive values were initially obtained and entered the next step of screening.
[0055] 4.4.2 Specificity screening.
[0056] The same operation as above was performed, human IgG was coated, and the cell wells with low reaction values were selected. The purpose of this screening step is to discard cells that have non-specific reactions with human IgG, and then screen out cells with high specificity for human IgM-Fc. Human IgG is prepared by purification from human serum by ion exchange chromatography.
[0057] Table 2 Cell-specific screening test results
[0058] Cell number IgM1 IgM2 IgM3 IgM4 IgM5 IgM6 OD value 0.415 0.183 0.159 0.311 0.206 0.308 Cell number IgM7 IgM8 IgM9 IgM10 Negative Positive OD value 0.602 0.165 0.287 0.220 0.120 1.003
[0059] After screening, IgM2, 3, 5, 8, and 10 cells with low nonspecific reactions were selected for the next screening step.
[0060] 4.4.3 Subtype screening.
[0061] The test was performed using the mouse monoclonal antibody Ig class / subclass identification ELISA kit from Biolon. The test results are shown in the following table. IgM2, 3, and 8 are IgG1 subtypes, and IgM5 and IgM10 are IgM subtypes.
[0062] Table 3 Cell line subtype detection results
[0063] IgM2 IgM3 IgM5 IgM8 IgM10 IgG1 2.106 2.031 0.205 1.992 0.553 IgG2a 0.112 0.110 0.103 0.115 0.125 IgG2b 0.105 0.098 0.101 0.109 0.089 IgG3 0.102 0.121 0.015 0.124 0.109 IgA 0.101 0.112 0.114 0.115 0.107 IgM 0.124 0.129 1.852 0.117 1.698
[0064] The preferred subtype is IgG1 subtype cell strain IgM2, 3, 8, which is convenient for subsequent purification and obtaining stable and high-yield antibodies.
[0065] 5. Screening and testing of cell line subcloning and passage stability
[0066] The cell wells that passed the above three steps were subcloned three times, and the cell lines with positive single cells in each subclone were screened for IgM2 and 3. After the subcloned cell lines were subcultured for 10 generations, the positive detection value was stable, and the IgM2 deviation was less than 10%. Figure 1 As shown in the figure, IgM2 and 3 are monoclonal cells that can stably secrete anti-human IgM, and the stability of IgM2 in continuous passage is better than that of IgM3.
[0067] 6. Screening and testing of cell line storage stability
[0068] The two cells IgM2 and 3 that passed the previous step were frozen and revived 10 times to select a hybridoma cell line with stable growth. The cell line that passed the previous step detection and screening requirements was determined to be a hybridoma cell line that can stably secrete anti-human IgM-Fc fragments.
[0069] like Figure 2As shown, after 10 times of freezing and thawing, the positive rate of IgM2 and 3 monoclonal antibody cell lines was 100%, and the deviation of IgM2 positive detection value was less than 5%, which was more stable than IgM3. Therefore, the IgM2 monoclonal cell line was determined to be a hybridoma cell line that can stably secrete anti-human IgM-Fc fragments.
[0070] 7. Storage of Cell Lines
[0071] The hybridoma cell line IgM2 that passed the above screening was expanded and cultured. When the cell density reached 80%, the cells were collected by centrifugation, and the cells were frozen in a cell freezing solution (10% DMSO + 70% complete culture solution + 20% fetal bovine serum) in a gradient (2-8°C for 1h, -20°C for 2h, -80°C overnight, in liquid nitrogen) and stored in liquid nitrogen for a long time.
[0072] Example 3: Preparation of anti-human IgM monoclonal antibody
[0073] 1. Ascites Preparation
[0074] BALB / c mice weighing more than 18 g were selected and intraperitoneally injected with 500 μl of liquid paraffin. One week later, 10 6 hybridoma cells / mouse, injection volume is 500μl / mouse. After 7-10 days, the mice are continuously observed, and when the abdomen is obviously swollen, the ascites is collected, centrifuged at 9000rpm for 15min, impurities are removed, and stored in a -20℃ refrigerator.
[0075] 2. Antibody Purification
[0076] The ascites was dissolved at room temperature, centrifuged at 9000rpm for 10min, filtered with qualitative filter paper and then degreased. The ascites was precipitated with saturated ammonium sulfate at a final concentration of 50%, and the precipitate was dissolved with 10mM PBS+150mMNaCl. The protein concentration was 10-20mg / ml. The antibody was purified by homemade human IgM-Fc immunoaffinity chromatography column with reference to Boglon CNBrActived Bestarose 4B. The antibodies eluted from the purification column were collected and loaded into a dialysis bag, and the antibodies were concentrated with sucrose to a concentration of about 5mg / ml, and then dialyzed in a buffer solution of 10mM PBS+150mMNaCl+final concentration of 5% sucrose to replace the eluent. The antibody stored in this buffer has excellent stability. The antibodies were collected, filtered through a sterile filter membrane with a pore size of 0.22μm, and stored in a -20℃ refrigerator for subsequent testing and verification.
[0077] 3. Purity identification
[0078] The antibody purified in the previous step was subjected to SDS-PAGE electrophoresis, with 10 μg added to each well. Figure 3 As shown, the purity of anti-human IgM monoclonal antibody 2 was ≥ 95%.
[0079] Example 4: Performance verification of monoclonal antibodies
[0080] 1. Antibody Activity Assay
[0081] The indirect ELISA method was used to detect the titer of the antibody. The test results are shown in Table 4:
[0082] Table 4 Monoclonal antibody activity test results
[0083]
[0084] The specific detection methods are as follows:
[0085] Dilute human IgM-Fc to 1μg / ml with coating solution, and coat 100μl / well on the ELISA plate, and coat overnight at 4℃. Wash the plate 3 times. Add 150μl of blocking solution to each well of the ELISA plate and incubate at 37℃ for 2h. Wash the plate 3 times. Dilute the antibody to be detected to 2mg / ml first, then dilute it to 1 / 1K, 10K, and 100K, and add it to the ELISA plate, 100μl / well, and incubate at 37℃ for 1h. Wash the plate 3 times. HRP-labeled goat anti-mouse antibody was diluted 1:40,000 and added to the ELISA plate, 100μl / well, and incubate at 37℃ for 1h. Wash the plate 5 times. Add 100μl of TMB colorimetric solution to each well of the ELISA plate, incubate at 37℃ for 10min; stop with 2M sulfuric acid, 50μl / well, and read the data at a wavelength of 450nm.
[0086] According to ELISA test, the titers of anti-human IgM2 monoclonal antibody and anti-human IgMμ chain monoclonal antibody were ≥1:100K. When diluted to 1:10K, the titer of anti-human IgM2 monoclonal antibody was better than that of anti-human IgMμ chain monoclonal antibody.
[0087] 2. Antibody specificity detection
[0088] The specificity of the antibody was tested by indirect ELISA. The test results are shown in Table 5.
[0089] Table 5 Monoclonal antibody specificity detection results
[0090]
[0091] The specific detection methods are as follows:
[0092] Dilute human IgG to 1μg / ml with coating solution, and coat 100μl / well on the ELISA plate, and coat overnight at 4℃. Wash the plate 3 times. Add 150μl of blocking solution to each well of the ELISA plate and incubate at 37℃ for 2h. Wash the plate 3 times. First dilute the antibody to be detected to 2mg / ml, then dilute it to 1 / 1K and 10K and add it to the ELISA plate, 100μl / well, and incubate at 37℃ for 1h. Wash the plate 3 times. HRP-labeled goat anti-mouse antibody was diluted 1:40,000 and added to the ELISA plate, 100μl / well, and incubate at 37℃ for 1h. Wash the plate 5 times. Add 100μl of TMB colorimetric solution to each well of the ELISA plate, incubate at 37℃ for 10min; stop with 2M sulfuric acid, 50μl / well, and read the data at a wavelength of 450nm.
[0093] Through the above tests, the specificity test of anti-human IgM monoclonal antibody 2 was negative, while the specificity test of anti-human IgMμ chain monoclonal antibody was positive, so the specificity of anti-human IgM monoclonal antibody 2 is better than that of anti-human IgMμ chain monoclonal antibody.
[0094] Example 5: Application of anti-human IgM monoclonal antibody 2 in the detection of Mycoplasma pneumoniae IgM antibody by colloidal gold immunochromatography
[0095] 1. Comparison of colloidal gold immunochromatographic reagent detection
[0096] The final concentration of the coated Mycoplasma pneumoniae natural antigen was 0.8-1.2 mg / ml, the final concentration of the anti-human IgM monoclonal antibody 2 of the present invention labeled with colloidal gold was 15-20 μg / ml, and the clinical serum was detected by colloidal gold immunochromatography, and the control was a commercially available finished reagent purchased from outside. Test results Figure 4-6 As shown:
[0097] Figure 4 In the figure, strong positive clinical samples 1 and 2: using the anti-human IgM monoclonal antibody 2 of the present invention (left), the positive color development is significantly better than the control (right). Strong positive clinical samples 3 and 4: using the anti-human IgM monoclonal antibody 2 of the present invention (left), the positive color development is the same as the control (right).
[0098] Figure 5 Medium-positive clinical sample 5: using the anti-human IgM monoclonal antibody 2 of the present invention (left), the positive color development is significantly better than the control (right). Weak-positive clinical samples 6, 7, and 8: using the anti-human IgM monoclonal antibody 2 of the present invention (left), the positive color development is significantly better than the control (right).
[0099] Figure 6 Middle, negative clinical samples 9-12: using the anti-human IgM monoclonal antibody 2 of the present invention (left), the results are consistent with the control (right).
[0100] Depend on Figure 4-6It can be seen from the test results that the anti-human IgM monoclonal antibody 2 of the present invention is applied to the Mycoplasma pneumoniae IgM antibody detection reagent, and the reagent accuracy is consistent with the purchased reagent, but the sensitivity is higher than the purchased finished reagent.
[0101] 2. Comparison of positive detection rate and specificity of colloidal gold immunochromatography
[0102] Clinically confirmed negative and positive samples were collected, and the anti-human IgM monoclonal antibody 2 of the present invention and the purchased anti-human IgM μ chain monoclonal antibody were labeled with the same process of colloidal gold immunochromatography, and the clinical detection rate and specificity were compared. The results are shown in Table 6, Table 7, Figure 7 As shown:
[0103] Table 6 Activity (positive detection rate) detection comparison
[0104]
[0105] Table 7 Comparison of specificity detection
[0106]
[0107]
[0108] Figure 7 Middle, negative clinical samples 13-17: The membrane surface is clean and has no background when using the anti-human IgM monoclonal antibody 2 of the present invention (left), which is significantly better than the control - purchased anti-human IgM μ chain monoclonal antibody (right).
[0109] From the above results, Table 6, Table 7, Figure 7 It can be seen that the anti-human IgM monoclonal antibody 2 of the present invention and the purchased anti-human IgM μ chain monoclonal antibody are respectively applied to the Mycoplasma pneumoniae IgM antibody detection reagent, and the positive detection rate is consistent. However, in terms of specificity and background, the anti-human IgM monoclonal antibody 2 of the present invention has a low false positive rate, a clean color background, and no non-specific reaction, which has obvious advantages.
[0110] In order to better demonstrate that the operation method of the present invention can improve the stability of antibodies during antibody purification, 4 comparative examples are provided in Table 8.
[0111] Table 8: Different antibody purification methods
[0112] Post-column concentration method concentration Storage buffer Example 3 sucrose 5mg / ml 10mM PBS+150mM NaCl+5% sucrose Comparative Example 1 PEG6000 5mg / ml 10mM PBS+150mM NaCl+5% sucrose Comparative Example 2 sucrose 5mg / ml 10mM PBS+150mM NaCl+2% sucrose Comparative Example 3 PEG6000 5mg / ml 10mM PBS+150mM NaCl+2% sucrose Comparative Example 4 Not concentrated 1mg / ml 10mM PBS+150mM NaCl+5% sucrose
[0113] The IgM monoclonal antibody 2 purified by the four methods in Table 8 was placed at 2-8°C for 2 weeks, and then labeled with the same final concentration and used in the detection of Mycoplasma pneumoniae IgM antibody detection reagent (colloidal gold immunochromatography). Figure 8-10 As shown:
[0114] Figure 8 :From left to right:
[0115]
[0116] Fig. 9 :From left to right:
[0117]
[0118]
[0119] Fig.10 :From left to right:
[0120]
[0121] Through the above tests, the activity and stability of anti-human IgM monoclonal antibody 2 after different purifications and storage in buffer at 2-8°C for 2 weeks, Example 3 is better than Comparative Example 2, better than Comparative Example 1, and better than Comparative Example 3 and Comparative Example 4. The method of concentrating and collecting after the column in antibody purification in Example 3 can significantly improve the stability of the antibody at 2-8°C.
[0122] It is understandable that those skilled in the art can make equivalent substitutions or changes based on the technical solution and concept of the present invention, and all these changes or substitutions should fall within the protection scope of the claims attached to the present invention.
Claims
1. An anti-human IgM monoclonal antibody hybridoma cell line, characterized in that: The hybridoma cell line is named IgM2, and its deposit number is CCTCC NO.C2024172.
2. The anti-human IgM monoclonal antibody hybridoma cell line according to claim 1, characterized in that: The preparation method of the hybridoma cell line IgM2 is: Based on the principle of hybridoma cells, the naturally purified human IgM-Fc fragment was used as the immunogen to quickly immunize mice and complete the preparation of hybridomas; the self-developed screening indicators and processes: positive (human IgM-Fc fragment), specificity (human IgG), subtype (IgG1 subtype), subcloning 3 times, cell passaging stability (continuous passaging for 10 generations), cell freezing stability (cryopreservation and recovery 10 times); finally, the anti-human IgM monoclonal antibody hybridoma cell line 2 with stable performance was screened out, namely IgM2.
3. An anti-human IgM monoclonal antibody, characterized in that: The antibody is secreted and produced by the hybridoma cell line according to claim 1.
4. An anti-human IgM monoclonal antibody according to claim 3, characterized in that: The preparation method of the monoclonal antibody is: The hybridoma cell line 2 was immunized with anti-human IgM monoclonal antibody, and mouse ascites was prepared. After precipitation with ammonium sulfate, the antibody was purified by a homemade human IgM-Fc immunoaffinity chromatography column. The antibody was then concentrated with sucrose, stored in a phosphate buffer containing a final concentration of 5% sucrose, and filtered through a sterile filter membrane with a pore size of 0.22 μm to obtain a high-purity and high-specificity anti-human IgM monoclonal antibody.
5. Use of the hybridoma cell line according to claim 1 in preparing a kit.
6. Use of the monoclonal antibody as claimed in claim 3 in preparing a kit.
7. The use according to any one of claims 5 or 6, characterized in that: The kit is a colloidal gold immunochromatography kit.
8. Use of the hybridoma cell line according to claim 1 in preparing a Mycoplasma pneumoniae IgM antibody detection reagent.
9. Use of the monoclonal antibody according to claim 3 in the preparation of a Mycoplasma pneumoniae IgM antibody detection reagent.
10. The use according to claim 9, characterized in that: The final concentration of the anti-human IgM monoclonal antibody is 15-20 μg / ml.
Citation Information
Cited By
Anti-human IgM antibody and kit for detecting human IgM
CN119684466A
